Tigecycline-Associated Acute Pancreatitis

Akhter, Sana; Krishnan, Prathik; Kaul, Pratibha

doi:10.1097/mjt.0000000000000763

Cited by 10 publications

(11 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…week of tigecycline treatment with symptoms resolving 24-48 hours after discontinuation. 16 Lin et al reported a case of a 48-year-old female renal transplant patient diagnosed with non-necrotizing Balthazar grade D pancreatitis on the 15th day of tigecycline. One…”

Section: Discussionmentioning

confidence: 99%

“…15 In 2018 Akhter et al reported a 61-year-old renal transplant recipient who developed AP on the 4th week of tigecycline treatment with symptoms resolving 24-48 hours after discontinuation. 16 Lin et al reported a case of a 48-year-old female renal transplant patient diagnosed with non-necrotizing Balthazar grade D pancreatitis on the 15th day of tigecycline. One week after the discontinuation of the drug, pancreatic enzymes returned to the baseline level.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

A case report of tigecycline induced acute pancreatitis in a renal transplant patient and review of the literature: Should we avoid tigecycline in patients on calcineurin inhibitors?

Yazirli

Kara

İnkaya

et al. 2021

Transplant Infectious Dis

View full text Add to dashboard Cite

Tigecycline is the first member of the glycylcycline family to be approved by the U. S. Food and Drug Administration to be used in complicated skin and soft tissue infections, complicated intra-abdominal infections, and community-acquired pneumonia due to its broadspectrum antibiotic activity. It inhibits bacterial protein synthesis via binding to the 30S ribosomal subunit. The main route of resistance against tetracycline is through the efflux pump. 1,2 This mechanism makes tigecycline preferable for the treatment of multi-drug resistant infections, however, both drugs have similar adverse effects. 1 Phase III studies revealed gastrointestinal side effects (ie nausea, vomiting, and diarrhea) as common adverse effects. 2,3 The first product label of tigecycline did not include pancreatitis as an adverse effect. AP was included after post-marketing surveillance in 2006. 4 Available data emerged from limited case reports in transplant patients on calcineurin inhibitors and the true incidence is unknown.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

A case report of tigecycline induced acute pancreatitis in a renal transplant patient and review of the literature: Should we avoid tigecycline in patients on calcineurin inhibitors?

Yazirli

Kara

İnkaya

et al. 2021

Transplant Infectious Dis

View full text Add to dashboard Cite

show abstract

“…[ 12 , 13 ] Relevant literature data in recent years have shown that reports of tigecycline-induced acute pancreatitis have increased significantly. [ 4 , 14 , 15 ]…”

Section: Discussionmentioning

confidence: 99%

Acute pancreatitis caused by tigecycline

Wang¹,

Hong²,

Zhu³

et al. 2021

Medicine

View full text Add to dashboard Cite

Rationale: There is evidence that tigecycline has broad-spectrum antibiotic activity against a variety of complicated infections. However, adverse effects are inevitable, including gastrointestinal side effects such as nausea, vomiting, and diarrhea; in 2006, acute pancreatitis was also brought into the side-effect list after postmarketing surveillance. Here, we present a case of tigecycline-induced acute pancreatitis. Patient concerns: An 87-year-old female patient with urinary tract infection received an intravenous drip of tigecycline for 6 days, after which she developed abdominal distension, vomiting, abdominal pain, and abdominal rigidity. Diagnosis: The patient was suspected to have tigecycline-induced acute pancreatitis. Interventions: Tigecycline was discontinued immediately, and the patient received a series of immediate treatments including an indwelling gastric tube for continuous gastrointestinal decompression and inhibition of gastric acid and pancreatic enzyme secretion. Outcomes: Following initial interventions, we observed that the patient's symptoms improved significantly, and abdominal distension, vomiting, abdominal pain, and abdominal rigidity were slightly relieved. After 5 days of follow-up, blood lipase and amylase levels decreased to normal levels. Unfortunately, the patient developed convulsions during the use of multiple antibiotics after 1 week and then died of septic shock and acute liver failure. Lessons: Acute pancreatitis caused by tigecycline is rare. However, in the application of antibiotics, the possibility of adverse effects must be considered, and antibiotics should be used reasonably. If the patient has relevant symptoms, it is necessary to stop using tigecycline immediately, carry out symptomatic treatment, and change to other types of antibiotics for antibacterial treatment.

show abstract

“…Tigecycline discontinuation was followed by regression of symptoms and drop of pancreatic enzymes [16]. The number of reported tigecycline pancreatitis is small and insufficient to lower its prescriptions [17]. Concerning tigecycline pancreatitis, the retrospective analyses of phases 3 and 4 clinical studies revealed mixed conclusion.…”

Section: Antibioticsmentioning

confidence: 99%

“…Concerning tigecycline pancreatitis, the retrospective analyses of phases 3 and 4 clinical studies revealed mixed conclusion. In respect to seriousness of acute pancreatitis, clinicians should be aware of this potential adverse effect and should monitor patients for features of pancreatitis during treatment with tigecycline [17].…”

Section: Antibioticsmentioning

confidence: 99%

Updates in drug-induced acute pancreatitis

Alhaddad

Elsabaawy

Elfauomy

et al. 2020

Egypt Liver Journal

View full text Add to dashboard Cite

Background Being infrequent, drug-induced acute pancreatitis (DIP) is an overlooked clinical entity that can be serious with significant morbidity and mortality. Main body A renovative review of drugs incriminated in acute pancreatitis had been presented with all relevant data and case presentations. Antibiotics, antidiabetics, antihypertensive agents, H2 blockers (H2B) and proton pump inhibitors (PPIs), anticancer therapies, and the new direct-acting antiviral therapies (DAAs) of hepatitis C virus (HCV) were discussed pertinently to DIP. Conclusions DIP should be suspected as a potential adverse event to every newly emerged drug. Herein, an updated review of drugs recently alleged to be implicated in DIP.

show abstract

Tigecycline-Associated Acute Pancreatitis

Cited by 10 publications

References 3 publications

A case report of tigecycline induced acute pancreatitis in a renal transplant patient and review of the literature: Should we avoid tigecycline in patients on calcineurin inhibitors?

A case report of tigecycline induced acute pancreatitis in a renal transplant patient and review of the literature: Should we avoid tigecycline in patients on calcineurin inhibitors?

Acute pancreatitis caused by tigecycline

Updates in drug-induced acute pancreatitis

Contact Info

Product

Resources

About